Clinical characteristics of the three patients with hepatic failure due to hepatitis B virus (HBV) reactivation after withdrawal of lamivudine
| Patient No | Age (y) | Sex | HBV status before chemotherapy | Time of HBV reactivation after initiation of chemotherapy | Time of HBV reactivation after lamivudine withdrawal | HBV DNA >104 copies/ml before chemotherapy | Elevated ALT before chemotherapy | Peak prothrombin time during hepatic failure (s) | Outcome | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HBsAg | HBeAg | Anti-HBe | |||||||||
| HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HBe, hepatitis B e antibody. | |||||||||||
| ALT, alanine aminotransaminase (normal range 13–51 U/l). | |||||||||||
| 1 | 51 | M | + | + | - | 16.0 | 7.6 | Yes | No | 68.1 | Died |
| 2 | 25 | M | + | + | - | 17.8 | 5.8 | Yes | No | 23.4 | Recovered |
| 3 | 57 | F | + | - | + | 24.7 | 13.8 | Yes | Yes | 28.2 | Recovered |